American Society of Gene & Cell Therapy (ASGCT) 17th Annual Meeting

美国基因学会

• 批准号: 8720363
• 负责人: David W Russell
• 金额: $ 1万
• 依托单位: AMERICAN SOCIETY OF GENE & CELL THERAPY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-15 至 2015-07-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8720363
• 关键词: American; Award; Awareness; Cell Therapy; Cells; District of Columbia; Education; Ethical Issues; Ethicists; Fostering; Funding; Genes; Genetic; Grant; Human; Knowledge; Mission; Oral; Participant; Peer Review; Postdoctoral Fellow; Process; Request for Proposals; Research; Scientific Advances and Accomplishments; Scientist; Societies; Students; Technology; Thinking; Time; Training; Travel; United States National Institutes of Health; Work; abstracting; base; clinical application; doctoral student; gene therapy; human disease; insight; meetings; member; posters; pre-doctoral; programs; public health relevance; symposium

DESCRIPTION (provided by applicant): American Society of Gene & Cell Therapy (ASGCT) was founded in 1996. ASGCT's mission is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. Our Annual Meeting represents the major educational initiative of the Society. This R13 proposal requests support for travel grants for trainees. Approximately 1/4 of our members are scientists in training working to develop clinically applicable gene and cell-based technologies. Trainee participation in the Annual Meeting is fostered by a distinctive educational program, numerous trainee travel awards, and recognition of outstanding scientific accomplishments through peer-reviewed trainee Excellence in Research Awards. Over the past decade, the ASGCT has offered 620 travel grants and 68 Research Awards, with 180 travel grants made possible by R13 grant awards from the NIH during that same time. Educational opportunities for travel awardees include exceptional plenary speakers, state-of-the-art scientific symposia, and educational sessions that review current thinking on a variety of topics. In addition to leading scientists and clinicians, the program includes ethicists and representatives from the FDA, OBA, and NIH so young scientists may gain insight into the compliance and ethical issues related to human gene therapy and cell therapy. Trainees are active presenters in oral abstract and poster presentations and the top trainee abstracts are recognized at the Presidential Symposium. The size of the ASGCT meeting (approximately 1,600 participants) is ideally suited to expose young scientists to leaders in the field, yet provide opportunities for trainees to present their work at the premier meeting in the field of gene and cell therapy. NIH support for the ASGCT Annual Meeting will allow continued educational and professional advancement of trainees in the field of cell and gene therapy in addition to the unique opportunity to network with leaders in the field.

美国基因与细胞治疗学会（ASGCT）成立于1996年。ASGCT的使命是促进知识、意识和教育，从而发现和临床应用基因和细胞疗法来减轻人类疾病。我们的年会代表了社会的主要教育举措。这一R13建议要求支持为受训人员提供旅费赠款。我们大约四分之一的成员是正在接受培训的科学家，致力于开发临床适用的基因和细胞技术。学员参加年会是由一个独特的教育计划，众多的学员旅行奖，并通过同行评审的优秀研究奖学员的杰出科学成就的认可。在过去的十年中，ASGCT提供了620个旅行赠款和68个研究奖，其中180个旅行赠款金是由NIH在同一时间提供的R13补助金。旅行获奖者的教育机会包括杰出的全体会议发言人，最先进的科学 研讨会和教育会议，审查当前对各种主题的思考。除了领先的科学家和临床医生，该计划还包括来自FDA，OBA和NIH的伦理学家和代表，因此年轻的科学家可以深入了解与人类基因治疗和细胞治疗相关的合规性和伦理问题。学员是口头摘要和海报演示的积极主持人，顶级学员摘要在总统研讨会上得到认可。ASGCT会议的规模（约1，600名与会者）非常适合让年轻科学家接触该领域的领导者，同时也为学员提供机会，在基因和细胞治疗领域的首要会议上介绍他们的工作。NIH对ASGCT年会的支持将使细胞和基因治疗领域的受训者能够继续获得教育和专业发展，此外还有与该领域领导者建立联系的独特机会。